Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$20.55
-3.0%
$21.88
$7.75
$27.17
$162.57M0.68142,714 shs55,530 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$49.89
+1.8%
$29.07
$6.45
$50.53
$932.10M1.061.10 million shs1.50 million shs
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
$2.00
$2.09
$1.85
$4.26
$135.66M1.58866,464 shs684,684 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$23.90
-0.4%
$16.71
$4.01
$30.00
$66.80M1.2632,466 shs10,644 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-3.02%-11.23%-19.22%+19.89%+11.99%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
+1.80%+2.72%+83.02%+479.44%+161.89%
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.00%0.00%0.00%0.00%0.00%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-0.25%-7.85%+54.76%+231.88%+273.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$20.55
-3.0%
$21.88
$7.75
$27.17
$162.57M0.68142,714 shs55,530 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$49.89
+1.8%
$29.07
$6.45
$50.53
$932.10M1.061.10 million shs1.50 million shs
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
$2.00
$2.09
$1.85
$4.26
$135.66M1.58866,464 shs684,684 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$23.90
-0.4%
$16.71
$4.01
$30.00
$66.80M1.2632,466 shs10,644 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-3.02%-11.23%-19.22%+19.89%+11.99%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
+1.80%+2.72%+83.02%+479.44%+161.89%
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.00%0.00%0.00%0.00%0.00%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-0.25%-7.85%+54.76%+231.88%+273.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.75
Moderate Buy$41.33101.14% Upside
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.86
Moderate Buy$88.3377.06% Upside
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.00
N/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ASMB, SLGL, NKTR, and SBBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$31.00 ➝ $39.00
8/19/2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
8/18/2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
7/8/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $85.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $100.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$120.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$28.52M5.53N/AN/A$5.25 per share3.91
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$98.43M9.64N/AN/A$4.94 per share10.10
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
$30.73M4.41N/AN/A$0.98 per share2.04
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$11.54M5.78N/AN/A$10.36 per share2.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$5.58N/AN/AN/A-117.20%-149.01%-39.04%11/6/2025 (Estimated)
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)

Latest ASMB, SLGL, NKTR, and SBBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/15/2025Q2 2025
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$0.67$4.17+$4.84$4.17$2.86 million$17.26 million
8/7/2025Q2 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million
8/6/2025Q2 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$1.73-$1.33+$0.40-$1.33$5.30 million$9.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
1.64
1.64
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
2.61
2.61
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.38
3.00
2.95
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
7.32
7.32

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
52.03%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
26.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.67 million7.28 millionOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22019.02 million18.31 millionOptionable
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
7267.83 millionN/AOptionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
502.79 million933,000Optionable

Recent News About These Companies

Sol-Gel Technologies (NASDAQ:SLGL) Upgraded to "Buy" at Wall Street Zen
Sol-Gel Announces Health Canada Approval of EPSOLAY®
Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance
SLGL Sol-Gel Technologies Ltd. - Seeking Alpha
Sol-Gel Technologies Ltd
Sol Gel Tech Stock Price History
Sol-Gel Reports First Quarter 2025 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$20.55 -0.64 (-3.02%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$20.50 -0.05 (-0.27%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$49.89 +0.88 (+1.80%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$51.60 +1.71 (+3.43%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Strongbridge Biopharma stock logo

Strongbridge Biopharma NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Sol-Gel Technologies stock logo

Sol-Gel Technologies NASDAQ:SLGL

$23.90 -0.09 (-0.35%)
Closing price 09/16/2025 03:58 PM Eastern
Extended Trading
$23.90 0.00 (0.00%)
As of 09/16/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.